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Abstract
Safety analyses in terms of adverse events (AEs) are an important aspect of benefit-
risk assessments of therapies. Compared to efficacy analyses AE analyses are often
rather simplistic. The probability of an AE of a specific type is typically estimated
by the incidence proportion, sometimes the incidence density or the Kaplan-Meier
estimator are proposed. But these analyses either do not account for censoring, rely
on a too restrictive parametric model, or ignore competing events. With the non-
parametric Aalen-Johansen estimator as the gold-standard, these potential sources of
bias are investigated in a data example from oncology and in simulations, both in the
one-sample and in the two-sample case. As the estimators may have large variances
at the end of follow-up, the estimators are not only compared at the maximal event
time but also at two quantiles of the observed times. To date, consequences for safety
comparisons have hardly been investigated in the literature. The impact of using dif-
ferent estimators for group comparisons is unclear, as, for example, the ratio of two
both underestimating or overestimating estimators may or may not be comparable to
the ratio of the gold-standard estimator. Therefore, the ratio of the AE probabilities is
also calculated based on different approaches. By simulations investigating constant
and non-constant hazards, different censoring mechanisms and event frequencies, we
show that ignoring competing events is more of a problem than falsely assuming con-
stant hazards by use of the incidence density and that the choice of the AE probability
estimator is crucial for group comparisons.
Keywords: Aalen-Johansen, acute myeloid leukemia, adverse events, competing events,
safety.
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1 Introduction
In clinical trials, safety analyses in terms of adverse events (AEs) are a key aspect of
benefit-risk assessments of therapies. Inappropriate analysis methods may result in mis-
leading conclusions about a therapy’s safety. This may lead to severe consequences for
patients within the trial when the analyses were conducted for safety monitoring or for
patients outside the trial when the therapy is used more widely following the trial.1 In
practice, the probability of an AE of a specific type is most often estimated by the inci-
dence proportion given by the number of patients experiencing the AE out of all patients
in the respective treatment group.2 As the incidence proportion does not account for the
time a patient is under observation, it ignores censoring and may lead to an underesti-
mation of the adverse event probability.1,3 To consider time under observation, survival
methods in form of the incidence density which divides by patient-time-at-risk are sug-
gested.4 In constrast to the incidence proportion, the incidence density, also called inci-
dence rate, is that it estimates a hazard and not of a probability. The incidence density can
be transformed to the probability scale as we will see later. This could be interpreted as a
parametric version of one minus the non-parametric Kaplan-Meier estimator, but impos-
ing the assumption of constant hazards over time, which is a typical point of criticism.5
Additionally to censoring, competing events (CEs) such as death or premature treatment-
related discontinuation of participation in the study can occur preventing the observation
of the AE.3 The Kaplan-Meier estimator and the probability transform of the incidence
density treat the CEs as censored observations and therefore do not account for CEs. As a
result, they overestimate the AE probability.6,7
An estimator accounting for all three potential sources of bias, namely censoring, non-
constant hazards and CEs, is the non-parametric Aalen-Johansen estimator.8 Therefore, it
is considered the gold standard. Under the assumption of constant hazards for theAE and
for the CE, a parametric version of the Aalen-Johansen estimator of the AE probability can
be constructed from these two hazards. This estimator is called the probability transform
of the incidence density accounting for CEs.
The problems related to biased estimation of the AE probability have been previously
described.1,3,4,9 Here we extend the discussion by investigating the following three ques-
tions: (i) What is the impact of choosing different estimators of the AE probabilities on
group comparisons in terms of bias and precision? (ii) Is the impact of ignoring CEs pos-
sibly worse than falsely assuming constant hazards? (iii) How does the time point of
analysis influence the previous two questions, especially for the incidence proportion?
Regarding question (i), one aspect of the benefit-risk assessment of safety analyses is
treatment comparisons in terms of the relative risk. The relative risk compares two treat-
ments by taking the ratio of the estimators of the experimental treatment and the control
treatment. Even if the used probability estimator may underestimate or overestimate the
AE probability, the ratio of two probability estimates, obtained with one of the biased es-
timators, may be comparable to the ratio of the probability estimates obtained with the
gold standard. In this paper additionally to the AE probability estimators also the vari-
ances of the AE probability estimators are investigated as misspecification of the hazard
in the form of falsely assuming constant hazards may also influence the variances of the
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parametric estimators. A non-parametric bootstrap is suggested as a suitable alterna-
tive to obtain the variance estimates.10 These bootstrapped variances are compared to the
asymptotic, model-based estimators to see whether the assumption of constant hazards
also impacts the variances. Question (ii) aims to investigate whether a misspecified inci-
dence density analysis that does account for CEs may be useful provided that variance
estimation accounts for misspecification. Question (iii) is a consequence of the problem
that the incidence proportion is usually only calculated at the end of follow-up in each
group of the two treatment groups. This leads to different evaluation time points in the
relative risk of the incidence proportion drawing the interpretation into question.11 To
solve this issue all comparisons are not only conducted at the end of follow-up but also
at the shorter of the two observed maximum follow-up times in the two groups. There is
also the concern that a low number of observations under study at the end of follow-up
leads to increased variances.12 Hence, the comparisons of the AE probability estimators
are also investigated at two different quantiles of the observed times.
We also note that Bender and Beckmann13 have recently investigated whether the
ratio of incidence densities may serve as an estimator of the hazard ratio even under mis-
specification. Their investigation was also motivated by AE analyses, also considered
variances (via confidence intervals) and found that results depend on the baseline cu-
mulative AE probability. However, these authors did neither consider competing events
(which impacts probabilities) nor bootstrapping variances (which may lead to larger con-
fidence intervals).
The paper is organized as follows, Section 2 introduces the AE probability estimators
with corresponding variance estimators. Section 3 presents the comparisons of the esti-
mators at the different follow-up times based on data from an oncology trial. In Section 4
a simulation study addresses the three questions posed above. The paper concludes with
a discussion in Section 5.
2 Estimators and their variances of event probabilities and their
ratios
2.1 Competing risks model
In the following we consider data from a two-arm randomized controlled trial with each
group following a competing risks model displayed in Figure 1. Every patient starts in
the initial state 0 at study entry, i.e., at time 0. The event time at which a patient i moves
from state 0 to either state 1 or 2, whatever is observed first, is denoted by Ti and the event
type is denoted by ǫi as ǫi = 1 in case of an AE and ǫi = 2 in case of a CE. A patient i can
also be censored at time Ci if Ci < Ti. Only the minimum of the censoring time Ci or the
event time Ti can be observed. Therefore, the observable data consists of i.i.d. replicates
of (min(Ti,Ci),1(Ti 6 Ci) · ǫi). Furthermore, Ti and Ci are assumed to be independent.
In this setting the AE hazard is defined as λ(t) = lim
n→∞P(T ∈ [t, t+dt), ǫ = 1|T > t)/∆t
and the hazard of the CE as λ¯(t) = lim
n→∞P(T ∈ [t, t + dt), ǫ = 2|T > t)/∆t respectively.
All estimators are evaluated at time τ. Later τwill take the values τ
(A)
max = max{min(Ti,Ci)|i in group A}
3
Study Entry
        0
Adverse Event 
(AE)     1
CE before AE
2
Figure 1: Competing risks setting.
and τ
(B)
max = max{min(T ,C)|i in group B} which are the maximum follow-up times in the
experimental group and control group, respectively. In general, τ
(A)
max 6= τ(B)max, but com-
paring both groups by evaluating estimators at the respective maximum follow-up time
is what is commonly done in the analyses of adverse events. But to refrain from observ-
ing one group much longer than the other, we also consider τmax = min(τ
(A)
max, τ
(B)
max),
τP90 = min(τ
(A)
P90 , τ
(B)
P90), with τ
(A)
P90 and τ
(B)
P90 the empirical 90% quantiles of min(T ,C) in
group A and B, respectively, and τP60 defined in the same way.
2.2 Estimators of event probabilities and their variances
The following five different estimators of the AE probability are considered and will be
compared. The estimators are only displayed for the experimental group A. For the con-
trol group B, they are derived analogously.
• Incidence proportion: Let dA(u) denote the number of observed AEs at time u in
group A and let nA be the total number of patients in group A, then the incidence
proportion is defined as
ÎPA(τ) =
∑
u∈(0,τ]
dA(u)
nA
,
where the sum is over all observed, unique event times u. The incidence proportion
estimates P(AE in [0, τ], AE observed). The correspondingmodel-based variance es-
timator is
sˆ2A =
ÎPA(τ)(1 − ÎPA(τ))
nA
.
• Probability transform incidence density: We first define the incidence density as
ÎDA(τ) =
∑
u∈(0,τ]
dA(u)
nA∑
i=1
min(ti, τ)
,
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where the denominator is the population time at risk restricted by τ with ti the
time of the first event irrespective of the event type of patient i. The model-based
variance estimator of the incidence density is
v̂ar(ÎDA)(τ) =
∑
u∈(0,τ]
dA(u)(
nA∑
i=1
min(ti, τ)
)2 .
The incidence density is an estimator of the hazard λA and as a consequence not
directly comparable to the incidence proportion. But by the assumption of constant
hazards and the connection to the exponential distribution it can be transformed to
the probability scale by 1− exp(−ÎDA(τ) · τ). If the assumption of constant hazards
holds, λA(t) = λA∀t, the incidence density is an unbiased estimator of the hazard.
Themodel-based variance estimator of the probability transform is sˆ2A = τ
2 ·exp(−τ·
ÎDA(τ))
2 · v̂arÎDA(τ), using the delta-method.
• 1- Kaplan-Meier: Let ∆ΛˆA(u) be the increment of the Nelson-Aalen estimator of the
cumulative AE hazard and therefore closely related to ÎDA(τ), then the 1-Kaplan-
Meier estimator is defined as
1− SˆA(τ) = 1−
∏
u∈(0,τ]
(
1− ∆ΛˆA(u)
)
.
The Kaplan-Meier estimator estimates the event-specific survival function SA(τ) =
exp
(
−
τ∫
0
λA(u) du
)
as it treats CEs by censoring the follow-up time. Its model-
based variance can be estimated using the Greenwood variance estimator.14 Note
that SA does not have a proper probability interpretation as a consequence of com-
peting events, see below.
• Aalen-Johansen estimator: As gold standard we consider here the Aalen-Johansen es-
timator which is given by
ÂJA(τ) =
∑
u∈(0,τ]
∏
v∈(0,u)
(
1− ∆ΛˆA(v) − ∆ΛˆA(v)
)
∆ΛˆA(u)
where ∆ΛˆA(v) is the increment of the Nelson-Aalen estimator of the CE. The model-
based variance of theAalen-Johansen estimator can be estimated using aGreenwood-
type estimator.15 The Aalen-Johansen estimator estimates the cumulative incidence
function P(T 6 τ, ǫ = 1| group A) =
τ∫
0
P(T > u − | group A)λA(u) du. Comparing
1 minus the event-specific survival function and the cumulative incidence function
it can be easily shown than 1 minus the event-specific survival function is greater
than the cumulative incidence function as long as CEs are present (see Appendix A
for details), and the same inequality holds for the 1-Kaplan-Meier estimator and the
Aalen-Johansen estimator.
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• Probability transform incidence density accounting for CEs:
ÎDA(τ)
ÎDA(τ) + ÎDA(τ)
(
1− exp(−τ[ÎDA(τ) + ÎDA(τ)])
)
,
where ÎDA(τ) =
∑
u∈(0,τ]
d¯A(u)/
nA∑
i=1
min(ti, τ) with d¯A(u) the number of observed
CEs at time u in group A, is the incidence density of the CE and, hence, the paramet-
ric analog of∆ΛˆA(τ). Using the incidence density of the CE, the connection between
the incidence density and the incidence proportion is ÎDA(τ)/(ÎDA(τ) + ÎDA(τ)) =∑
u∈(0,τ]
dA(u)/nA in the absence of censoring.
16 Moreover, a model-based variance
estimator of the estimator of the probability transform of the incidence density ac-
counting for CEs can be derived with the delta-method17 and is provided in the
Appendix B. In the following, we will also call the probability transform of the inci-
dence density accounting for CEs, somewhat loosely, parametric counterpart of the
Aalen-Johansen estimator as the two estimators estimate the same quantity under
the parametric assumption of constant hazards.
Anotherway to estimate the variances of the estimators is with a non-parametric boot-
strap accounting for model misspecifications that may also influence the model-based
variances.10 The variances of the parametric estimators given above assume that the haz-
ards are constant. This assumption is not made by the non-parametric bootstrap.
2.3 Between group comparisons
The comparison of the two treatment groups can be done in terms of the relative risk
R̂R(τ) =
pˆA(τ)
pˆB(τ)
,
where pˆA(τ) is one of the above introduced estimators of the AE probability in the in-
terval [0, τ]. The variance estimator of the relative risk can be constructed based on a
log-transformation
v̂ar(log R̂R(τ)) =
1
pˆA(τ)2
· sˆA(τ)2 +
1
pˆB(τ)2
· sˆB(τ)2,
where sˆA(τ)
2 and sˆB(τ)
2 are one of the two suggested variance estimators of pˆA(τ) and
pˆB(τ) evaluated at time τ.
3 An example: The DECIDER trial in acute myeloid leukemia
As an example we use data from the DECIDER trial (DECItabine, DEacetylase inhibi-
tion, Retinoic acid; ClinicalTrials.gov identifier: NCT00867672).18,19 This randomized,
multicenter trial had the objective to investigate the efficacy and safety of valproate and
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Figure 2: Adverse event probability estimators applied to the DECIDER trial at the differ-
ent follow-up times. The symbols have been jittered for better readability.
ATRA in combination with decitabine in 200 older and nonfit patients with acute myeloid
leukemia. The trial had a 2 x 2 design, in which patients were randomly assigned to 1 of
4 treatment arms: decitabine, decitabine + valproate, decitabine + ATRA, or decitabine +
valproate + ATRA. Here, we consider the comparison of the combined ATRA treatment
arms (called group A, nA = 96) with the combined no ATRA treatment arms (called
group B, nB = 104) with respect to the adverse event severe thrombocytopenia, Common
Terminology Criteria for Adverse Events (CTCAE) grade 3-5. This AE was observed in 35
patients in groupA and in 32 patients in group B. Death and end of treatment plus 28 days
with no observed AE during that time were considered as CEs. As ATRA prolonged over-
all survival time (median of 8.2 months in group A and of 5.1 months in group B19), a CE
was experienced by 56 patients in groupA and by 69 patients in group B, leading on aver-
age to a longer follow-up time for AEs in group A (mean 137 days) as compared to group
B (mean 125 days). So in this data set there is hardly any censoring as only 5 patients
in group A and 3 patients in group B were censored. The time was measured in days
and analyses were performed at τ
(A)
max = 802, respectively τ
(B)
max = 980, the maximum
follow-up times in the two groups, at τmax = 802 the minimum of the two maximum
follow-up times, at τP90 = 353 and at τP60 = 67, both chosen according to the quantiles of
the observed times.
3.1 Estimating the AE probability
Figure 2 displays the five different AE probability estimators for the four different follow-
up times. In the original analysis of the trial, the AE probabilites were estimated at τ
(A)
max,
τ
(B)
max using the incidence proportion, leading to an estimated probability of severe throm-
bocytopenia of 36.5% in group A and of 30.8% in group B19. This difference was not re-
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Figure 3: Cumulative hazard and 95% pointwise confindence intervals (95% CI) of the ad-
verse event and the competing event in both treatment groups. The vertical lines display
the analysis times.
garded as relevant taking into account the superiority of group A with respect to overall
survival. Now considering the other estimators, the probability transform of the incidence
density results in a higher estimated AE probability than the Aalen-Johansen estimator at
all follow-up times. The difference is more pronounced for longer follow-up times as
the CEs are observed later in time. The 1-Kaplan-Meier estimator also always obtains a
higher estimated AE probability than the Aalen-Johansen estimator but less pronounced
than the probability transform of the incidence density. For the latter, the estimated cu-
mulative hazards in Figure 3 illustrate departures from the constant hazard assumption.
Moreover, Figure 3 shows that CEs tend to occur later in time than AEs. This is the rea-
son why the difference between the probability transform of the incidence density or the
1-Kaplan-Meier estimator and the Aalen-Johansen estimator is larger at later follow-up
times.
The other three estimators differ only slightly. The probability transform of the inci-
dence density accounting for CEs is comparable to the Aalen-Johansen estimator. Even
though the assumption of constant hazards is not valid the difference between the two
estimators that account for the CE is nearly negligible. The incidence proportion takes the
same value as the Aalen-Johansen estimator as long as there are no censored observations
in the data.16 In these data, there is hardly any censoring but the last patient under obser-
vation in group B is censored leading to a slightly lower incidence proportion compared
to the Aalen-Johansen estimator. When estimating the probabilities at earlier follow-up
times this difference is less pronounced as in these situations the last observation in both
groups is always an AE or a CE.
8
3.2 Variance estimation
The variances of the probability estimators are calculated in two ways, first by using the
formulas displayed in Section 2 and second by a non-parametric bootstrap.
Table 1: Estimated variances of the AE probabilities using the analytically derived model-
based variances and bootstrapped variances. The following follow-up times are consid-
ered τ
(A)
max,τ
(B)
max the maximum follow-up times in group A and group B respectively,
τmax the minimum of the two maximal event times, τP90 and τP60 chosen according to
the quantiles of the time and account for different lengths of follow-up between group A
and group B.
Group A Group B
Follow-up time Estimator model-based bootstrap model-based bootstrap
τ
(A)
max,τ
(B)
max Incidence proportion 0.0024 0.0025 0.0020 0.0019
τ
(A)
max, τ
(B)
max Probability transform incidence density 0.0018 0.0036 0.0014 0.0034
τ
(A)
max, τ
(B)
max 1-Kaplan-Meier 0.0054 0.0060 0.0419 0.0509
τ
(A)
max, τ
(B)
max Aalen-Johansen 0.0024 0.0025 0.0022 0.0020
τ
(A)
max, τ
(B)
max Probability transform incidence density CE 0.0026 0.0026 0.0021 0.0020
τmax Incidence proportion 0.0024 0.0025 0.0020 0.0019
τmax Probability transform incidence density 0.0018 0.0041 0.0025 0.0045
τmax 1-Kaplan-Meier 0.0054 0.0060 0.0062 0.0067
τmax Aalen-Johansen 0.0024 0.0025 0.0020 0.0019
τmax Probability transform incidence density CE 0.0026 0.0027 0.0022 0.0021
τP90 Incidence proportion 0.0024 0.0024 0.0020 0.0019
τP90 Probability transform incidence density 0.0039 0.0059 0.0044 0.0049
τP90 1-Kaplan-Meier 0.0031 0.0036 0.0062 0.0047
τP90 Aalen-Johansen 0.0024 0.0024 0.0020 0.0019
τP90 Probability transform incidence density CE 0.0026 0.0028 0.0022 0.0021
τP60 Incidence proportion 0.0023 0.0022 0.0018 0.0016
τP60 Probability transform incidence density 0.0030 0.0032 0.0025 0.0023
τP60 1-Kaplan-Meier 0.0026 0.0024 0.0021 0.0018
τP60 Aalen-Johansen 0.0023 0.0022 0.0018 0.0016
τP60 Probability transform incidence density CE 0.0024 0.0027 0.0017 0.0017
Table 1 displays the estimated variances of all estimators for both groups evaluated at
the different follow-up times. At the maximal follow-up time in each group, two major
points can be observed. Firstly, the variance of the 1-Kaplan-Meier estimator is much
larger than all other variances. This verifies the expectation that at later follow-up times
the variance of the Kaplan-Meier estimator is increased due to a small number of patients
still at risk and this is the motivation for comparing also at the other follow-up times.12
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Also for shorter follow-up, except for τP60, this increased variance can be observed. At
τP60 all variances are virtually the same.
Secondly, for the probability transform of the incidence density the model-based vari-
ance is smaller than the bootstrapped variance. This is likely due to the model misspeci-
fication as the constant hazard assumption might not hold for the AE hazard as Figure 3
suggests. Again this effect is more pronounced for longer follow-up times than for τP60.
The two variance estimators of the Aalen-Johansen estimator and of the probability
transform of the incidence density accounting for CEs are almost identical as, like the
incidence proportion, they aim to estimate the binomial probability P(AE in [0, t]).
3.3 Group comparisons
We investigate how the ratio of two biased estimators of the probabilities compares to the
ratio of two unbiased estimators. Table 2 displays the relative risks calculated from the
estimators and time points shown in Figure 2. Additionally, the 95% confidence intervals
of the relative risk calculated with both variance estimators are displayed.
The relative risks calculated by the incidence proportion and the Aalen-Johansen es-
timator only differ at the maximal follow-up time. This is a direct consequence of the
last patient under observation in group B being censored leading to a slightly lower AE
probability estimated by the incidence proportion than by the Aalen-Johansen estimator
in group B.
At all follow-up times, the relative risk estimatedwith the probability transform of the
incidence density and the one estimated with the 1-Kaplan-Meier estimator are smaller
than the relative risk obtained with the gold standard Aalen-Johansen estimator. At the
maximum follow-up time, the direction of the estimated relative risks is different. But
note that the 1 is always included in the confidence interval indicating no statistically
significant therapy effects.
The relative risk estimated by the probability transform of the incidence density ac-
counting for CEs and the relative risk estimated by the Aalen-Johansen are similar at the
later follow-up times. At τP60 the relative risk estimated by the probability transform of
the incidence density accounting for CEs is greater than the one estimated by the Aalen-
Johansen estimator.
The differences between the confidence intervals obtained with the model-based and
with the bootstrapped variances are due to differences in the estimated variances. The
possible impact of this is illustrated by the fact that the relative risk estimated with the
Aalen-Johansen estimator is not included in the model-based confidence interval of the
probability transform of the incidence density at the maximal follow-up time and at τP90
but it is included in the confidence interval obtained with the bootstrapped variance.
Furthermore, the model-based confidence intervals of the incidence proportion and
the Aalen-Johansen estimator are longer than the confidence interval where the variances
are obtained with a bootstrap. For the probability transform of the incidence density and
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Table 2: Relative risk (RR), model-based confidence interval (CI), bootstrap CI and the
ratio of the lengths of the two confindence intervals (model-based/bootstrap) calculated
from the different AE probability estimators at several follow-up times.
model-based bootstrap ratio of
CI CI the lengths
Follow-up time Estimator RR Lower Upper Lower Upper of the CIs
τ
(A)
max, τ
(B)
max Incidence proportion 1.1849 0.8015 1.7517 0.8055 1.7429 1.0138
τ
(A)
max, τ
(B)
max Probability transform incidence density 0.9678 0.8540 1.0968 0.8053 1.1631 0.6786
τ
(A)
max, τ
(B)
max 1-Kaplan-Meier 0.6280 0.3294 1.1971 0.3105 1.2703 0.9041
τ
(A)
max, τ
(B)
max Aalen-Johansen 1.1550 0.7805 1.7092 0.7843 1.7008 1.0134
τ
(A)
max, τ
(B)
max Probability transform incidence density CE 1.2097 0.8217 1.7810 0.8259 1.7719 1.0140
τmax Incidence proportion 1.2231 0.8233 1.8172 0.8259 1.8114 1.0085
τmax Probability transform incidence density 1.0277 0.8857 1.1924 0.8337 1.2668 0.7082
τmax 1-Kaplan-Meier 1.0415 0.6449 1.6820 0.6296 1.7230 0.9485
τmax Aalen-Johansen 1.2231 0.8233 1.8172 0.8259 1.8114 1.0085
τmax Probability transform incidence density CE 1.2259 0.8294 1.8120 0.8317 1.8069 1.0075
τP90 Incidence proportion 1.1882 0.7965 1.7724 0.8036 1.7567 1.0240
τP90 Probability transform incidence density 1.0594 0.8052 1.3938 0.7756 1.4469 0.8767
τP90 1-Kaplan-Meier 0.9140 0.5808 1.4384 0.5939 1.4066 1.0553
τP90 Aalen-Johansen 1.1882 0.7965 1.7724 0.8036 1.7567 1.0240
τP90 Probability transform incidence density CE 1.2062 0.8159 1.7833 0.8097 1.7970 0.9799
τP60 Incidence proportion 1.3867 0.8899 2.1608 0.9067 2.1207 1.0468
τP60 Probability transform incidence density 1.3719 0.9021 2.0863 0.9067 2.0759 1.0128
τP60 1-Kaplan-Meier 1.3588 0.8683 2.1263 0.8883 2.0785 1.0569
τP60 Aalen-Johansen 1.3867 0.8899 2.1608 0.9067 2.1207 1.0468
τP60 Probability transform incidence density CE 1.4800 0.9549 2.2937 0.9445 2.3191 0.9739
the 1-Kaplan-Meier estimator at τ
(A)
max, τ
(B)
max and τmax, for the probability transform of
the incidence density at τP90 and for the probability transform of the incidence density
accounting for CEs at τP90 and τP60 the confidence interval based on the bootstrapped
variance is longer than the model-based confidence interval. This is also due to the differ-
ences in the estimated variances.
In summary, in this data example, estimators that lead to a higher estimate of the AE
probability than the Aalen-Johansen estimator result in a smaller relative risk estimate
than that based on the Aalen-Johansen estimator. The model based CIs of the probability
transform of the incidence densitymay be too small in the sense that they do not cover the
gold-standard estimate of the RR, but the bootstrapped CIs do not have this shortcoming.
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4 Simulation Study
In this section, we take a closer look at the three sources of bias namely, censoring, CEs and
non-constant hazards. For this purpose, competing risk datawith the event of interest and
one CE are simulated for two independent groups A and B.20 Table 3 describes the simu-
lation scenarios. The simulation scenarios marked with ⋆ are displayed in the following.
These represent all main findings of the investigation. The results of the other simula-
tion scenarios can be found in the Supplementary Material. For each scenario N = 1000
datasets are simulated.
Table 3: Summary of the scenarios considered in the simulation study (N = 1000).
Scenario λA(t) λ¯A(t) λB(t) λ¯B(t) nA = nB censoring
S1 constant 0.00265 0.00424 0.00246 0.00530 200 no
S2 constant ⋆ 0.00265 0.00424 0.00246 0.00530 400 no
S3 constant ⋆ 0.00265 0.00424 0.00246 0.00530 400 28% in A; 15% in B
S4 time-dependent 13t
2 8
9t
1.8
t+0.5
8
9t 400 no
S5 time-dependent ⋆ 13t
2 8
9t
1.8
t+0.5
8
9t 400 14% in A; 10% in B
S6 time-dependent 1.8
t+2
1
2t
1.8
t+2
1
8t 400 18.5% in A and B
S7 time-dependent 1.8
t+2
1
2t
1.8
t+2
1
8t 400 no
S8 time-dependent 12t
1.8
t+2
1
8t
1.8
t+2 400 no
S9 time-dependent 12t
1.8
t+2
1
8t
1.8
t+2 400 18.5%in A and B
S10 constant - time-dependent ⋆ 0.07 0.066 · t−0.283 0.06 0.042 · t−0.283 400 1.7% in A; 2.3% in B
Scenarios S1, S2 and S3 consider constant hazards for both events. The hazards are
equal to the incidence densities estimated in the data example presented in Section 3. The
hazards λA(t) and λB(t) correspond to the AE hazards and the hazards λ¯A(t) and λ¯B(t)
to the CE hazards in group A and group B, respectively. In contrast, scenarios S4 - S10
investigate the case where at least one hazard is time-dependent. In the scenarios S1,
S2, S4, S7 and S8 the data is completely observed, i.e. without censoring. In scenarios
S3, S5, S6 and S9 between 10 and 28 percent of the observations are censored whereas
in the scenario S10 similar to the data example only very little censoring is present. The
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censoring times were generated from an uniform distribution and are independent of the
event times.
4.1 Probability estimators
Table 4 displays the simulation results with regard to the AE probability estimates. The
table shows four important quantities of the comparison: the mean true simulated value,
the mean Aalen-Johansen estimator which is considered the gold standard, the absolute
mean bias with respect to the Aalen-Johansen estimator of the estimators and the relative
mean bias with respect to the Aalen-Johansen estimator.
For more stable results in the calculation of the mean true value and the mean Aalen-
Johansen estimator the mean was calculated on the logit-transformed results and back-
transformed to the probability scale. For the same reason in calculation of the relative
mean bias with respect to the Aalen-Johansen estimator the mean was calculated on the
log ratios and then exp-transformed back to the original scale. As in the data example the
comparisons are also conducted at several follow-up times. Note that τ
(A)
max, τ
(B)
max, τmax,
τP90 and τP60 take different absolute values in each simulation run. Therefore, as the true
value depends on the follow-up time, it is not the same value for all simulation runs, but
one for each simulation run. E.g., the true value for probability of the event of interest in
group A is calculated by P(T 6 τ, ǫ = 1|group A) =
τ∫
0
exp(−
u∫
0
λA(t) + λ¯A(t)dt)λA(u)du.
For this reason, we calculate the mean true value over all N = 1000 simulation runs. The
reason why the other estimators are compared to the Aalen-Johansen estimator is two-
fold. On the one hand, in the analyses of AE the true value is unknown. Therefore, the
simulations show the bias induced by using one of the non-gold-standard estimators com-
pared to using the gold-standard estimator. On the other hand, Table 4 also displays that
the Aalen-Johansen value and the true value are equal rounding to the second decimal
point.
The incidence proportion underestimates the AE probability if censoring is present,
and therefore, at all follow-up times in scenarios S3, S5 and S10. Under a large percentage
of censoring as in scenario S3 at the maximum follow-up time the AE probability esti-
mated by the incidence proportion is on average about 24% smaller than the AE proba-
bility estimated by the Aalen-Johansen estimator. As long as there is no censoring present
the incidence proportion coincides with the Aalen-Johansen estimator (scenario S2 with a
relative mean bias w.r.t. Aalen-Johansen of 0).
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Table 4: Simulation results: Mean Aalen-Johansen estimator (AJE), mean absolute and
mean relative bias w.r.t. Aalen-Johansen estimator. The following follow-up times are
considered τ
(A)
max,τ
(B)
max the maximum follow-up times in group A and group B respec-
tively, τmax the minimum of the two maximal event times, τP90 and τP60 chosen accord-
ing to the quantiles of the time and account for different lengths of follow-up between
group A and group B. For a better display probability transform is abbreviated by PT.
(N = 1000)
Group A Group B
Scenario Scenario
Follow-up time Estimator S2 S3 S5 S10 S2 S3 S5 S10
mean true simulated values
τ
(A)
max,τ
(B)
max true 0.3837 0.3695 0.1305 0.6088 0.3163 0.3079 0.8551 0.6928
τmax true 0.3826 0.3672 0.1219 0.6086 0.3161 0.3073 0.8551 0.6875
τP90 true 0.3333 0.2990 0.0226 0.5329 0.2842 0.2586 0.8068 0.5571
τP60 true 0.2128 0.1785 0.0010 0.3286 0.1891 0.1600 0.5708 0.3130
mean gold standard AE probability
τ
(A)
max, τ
(B)
max Aalen-Johansen 0.3857 0.3717 0.1309 0.6107 0.3167 0.3077 0.8571 0.6925
τmax Aalen-Johansen 0.3840 0.3692 0.1195 0.6101 0.3162 0.3071 0.8571 0.6854
τP90 Aalen-Johansen 0.3335 0.3002 0.0191 0.5340 0.2846 0.2582 0.8042 0.5563
τP60 Aalen-Johansen 0.2128 0.1790 0.0003 0.3276 0.1888 0.1598 0.5640 0.3121
Difference to AJE (mean absolute bias w.r.t. Aalen-Johansen)
τ
(A)
max, τ
(B)
max Incidence proportion -0.0000 -0.0945 -0.0223 -0.0119 -0.0000 -0.0714 -0.0275 -0.0174
τ
(A)
max, τ
(B)
max PT incidence density 0.5259 0.3415 0.1364 0.3751 0.5508 0.3679 0.1400 0.2981
τ
(A)
max, τ
(B)
max 1-Kaplan-Meier 0.5466 0.3460 0.6155 0.3857 0.5683 0.3689 0.1074 0.3055
τ
(A)
max, τ
(B)
max PT incidence density CE -0.0009 -0.0007 -0.0157 -0.0021 -0.0007 -0.0007 0.0068 -0.0025
τmax Incidence proportion -0.0000 -0.0922 -0.0191 -0.0119 -0.0000 -0.0709 -0.0275 -0.0164
τmax PT incidence density 0.4910 0.3283 0.0832 0.3748 0.5387 0.3612 0.1401 0.2879
τmax 1-Kaplan-Meier 0.4973 0.3322 0.3328 0.3827 0.5458 0.3641 0.1069 0.2890
τmax PT incidence density CE -0.0003 -0.0005 -0.0179 -0.0017 -0.0005 -0.0008 0.0069 0.0005
τP90 Incidence proportion -0.0000 -0.0501 -0.0015 -0.0072 -0.0000 -0.0413 -0.0204 -0.0083
τP90 PT incidence density 0.2057 0.1398 0.0018 0.2285 0.2288 0.1561 0.0846 0.1537
τP90 1-Kaplan-Meier 0.2055 0.1392 0.0049 0.2309 0.2315 0.1564 0.0379 0.1538
τP90 PT incidence density CE -0.0001 -0.0002 -0.0016 0.0082 -0.0005 -0.0004 0.0220 0.0086
τP60 Incidence proportion -0.0000 -0.0148 -0.0000 -0.0021 -0.0000 -0.0129 -0.0072 -0.0020
τP60 PT incidence density 0.0537 0.0348 0.0000 0.0734 0.0606 0.0395 0.0173 0.0451
τP60 1-Kaplan-Meier 0.0532 0.0343 0.0000 0.0733 0.0607 0.0393 0.0053 0.0444
τP60 PT incidence density CE -0.0001 -0.0001 -0.0000 0.0063 -0.0003 -0.0003 0.0089 0.0046
Ratio to AJE - 1 (mean relative bias w.r.t. Aalen-Johansen)
τ
(A)
max, τ
(B)
max Incidence proportion -0.0000 -0.2535 -0.1696 -0.0196 -0.0000 -0.2312 -0.0322 -0.0251
τ
(A)
max, τ
(B)
max PT incidence density 1.3654 0.9219 1.0341 0.6156 1.7405 1.1982 0.1638 0.4316
τ
(A)
max, τ
(B)
max 1-Kaplan-Meier 1.4145 0.9150 4.5261 0.6329 1.7813 1.1728 0.1254 0.4423
τ
(A)
max, τ
(B)
max PT incidence density CE -0.0024 -0.0010 -0.1189 -0.0034 -0.0022 -0.0014 0.0079 -0.0036
τmax Incidence proportion -0.0000 -0.2492 -0.1574 -0.0195 -0.0000 -0.2300 -0.0322 -0.0240
τmax PT incidence density 1.2800 0.8917 0.6716 0.6157 1.7051 1.1786 0.1639 0.4210
τmax 1-Kaplan-Meier 1.2910 0.8866 2.5790 0.6286 1.7137 1.1607 0.1247 0.4225
τmax PT incidence density CE -0.0008 -0.0006 -0.1492 -0.0027 -0.0015 -0.0016 0.0081 0.0008
τP90 Incidence proportion -0.0000 -0.1665 -0.0713 -0.0135 -0.0000 -0.1597 -0.0254 -0.0148
τP90 PT incidence density 0.6165 0.4652 0.0811 0.4288 0.8048 0.6048 0.1054 0.2766
τP90 1-Kaplan-Meier 0.6150 0.4617 0.2230 0.4334 0.8134 0.6040 0.0472 0.2765
τP90 PT incidence density CE -0.0004 -0.0004 -0.0746 0.0153 -0.0019 -0.0015 0.0273 0.0155
τP60 Incidence proportion -0.0000 -0.0820 -0.0254 -0.0063 -0.0000 -0.0805 -0.0127 -0.0065
τP60 PT incidence density 0.2513 0.1936 0.0034 0.2246 0.3212 0.2469 0.0307 0.1441
τP60 1-Kaplan-Meier 0.2486 0.1902 0.0244 0.2245 0.3216 0.2451 0.0094 0.1417
τP60 PT incidence density CE -0.0003 -0.0006 -0.0159 0.0191 -0.0018 -0.0016 0.0158 0.0148
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The probability transform of the incidence density is always higher than the AE prob-
ability estimated with the Aalen-Johansen estimator. The 1-Kaplan-Meier estimator is
also always higher. This difference is the most pronounced in scenario S5 in group A as
this is the scenario with the most CEs. At the maximum follow-up time in group A the
AE probability estimated by the 1-Kaplan-Meier estimator is on average about 452.61%
increased compared to the AE probability estimated by the gold standard. For smaller
follow-up times the differences between the estimators are less pronounced since less
CEs are present. Furthermore, it is notable that for group A in scenario S5 there is a huge
difference between the estimate of the probability transform of the incidence density and
the 1-Kaplan-Meier estimator. Due to the quadratic term in the hazard of the event of in-
terest the assumption of constant hazards for the AE hazard is severely violated resulting
in quite different estimates of the two estimators that censor CEs.
The bias between the probability transform of the incidence density accounting for
CEs and the Aalen-Johansen estimator is negligible under constant hazards in scenario S2
and S3. On the other hand, if both hazards are non-constant (scenario S5) the probability
transform of the incidence density accounting for CEs underestimates the event probabil-
ity. In group B of scenario S5 at all follow-up times and in scenario S10 at τP60 and τP30
the probability transform of the incidence density accounting for CEs is higher than the
Aalen-Johansen estimator. In all other scenarios respectively at all other follow-up times,
it is the other way around.
The difference between the 1-Kaplan-Meier estimator and the Aalen-Johansen esti-
mator is larger than the one between the parametric counterpart of the Aalen-Johansen
estimator and the estimator itself. Only in scenario S5 in group B at τP60 the mean bias
w.r.t. the Aalen-Johansen estimator of the probability transform of the incidence density
accounting for CEs is higher than the one of the Kaplan-Meier estimator. Generally, it
seems that ignoring CEs may be more harmful than falsely assuming constant hazards.
4.2 Variance estimators
Analogously to the data example the estimated variances are calculated model-basedwith
the formulas from Section 3.2 and with a non-parametric bootstrap. The boxplots in Fig-
ure 4 display the estimated variances in all simulation scenarios for all considered proba-
bility estimators.
Considering the boxplots of the variances of the estimators one immediately notices
the increased variances of the Kaplan-Meier estimator for the scenarios S2, S3 and for
group A of S5. The reason for these outliers is that, if the last event is an AE, the Kaplan-
Meier estimator equals 0 and as a consequence the 1-Kaplan-Meier estimate remaines un-
changed at 1 near the end of follow-up in some of the bootstrap replications. The model-
based variance using the Greenwood estimator is slightly smaller but still increased com-
pared to the other estimators. This problem was already mentioned in Pocock et al.
(2002)12 and is the motivation why we also consider some earlier follow-up times. Late
censored observations and late CEs as present in group B of scenario S5 and in scenario
S10 prevent the Kaplan-Meier estimator from dropping to 0 and therefore result in a
smaller variance.
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Figure 4: Boxplots of the estimated variances for each simulation scenario. The variances
are estimated by two different approaches, model-based and bootstrap. The following
follow-up times are considered τ
(A)
max,τ
(B)
max the maximum follow-up times in group A
and group B respectively, τmax the minimum of the two maximal event times, τP90 and
τP60 chosen according to the quantiles of the time and account for different lengths of
follow-up between group A and group B. (N = 1000)
16
Table 5: Simulation results: true mean relative risk (RR) and mean relative risk calculated
with the Aalen-Johansen estimator (AJE). The following follow-up times are considered
τ
(A)
max,τ
(B)
max the maximum follow-up times in group A and group B respectively, τmax the
minimum of the twomaximal event times, τP90 and τP60 chosen according to the quantiles
of the time and account for different lengths of follow-up between group A and group B.
(N = 1000)
Scenario
Follow-up time S2 S3 S5 S10
true simulated RR
τ
(A)
max,τ
(B)
max 1.2132 1.2000 0.1526 0.8787
τP60 1.2103 1.1950 0.1425 0.8853
τP90 1.1728 1.1561 0.0280 0.9567
τP60 1.1254 1.1157 0.0018 1.0499
mean relative RR calculated with AJE
τ
(A)
max,τ
(B)
max 1.2180 1.2078 0.1527 0.8820
τmax 1.2142 1.2020 0.1394 0.8904
τP90 1.1718 1.1625 0.0237 0.9605
τP60 1.1267 1.1200 0.0004 1.0508
Furthermore, the parametric counterpart of the Kaplan-Meier estimator is less sensi-
tive to the type of the last event. The variance of this estimator has only few outliers at
the end of follow-up. In this comparison the parametric estimator has a smaller variance
than the non-parametric Kaplan-Meier estimator.
In scenario S10 in group B an increased variance for earlier follow-up times can be
detected. The reason is that censoring, increasing the variance, occurs early and the last
event is rarely censored.
However, it is notable that differences between the estimated variances of the non-
parametric Aalen-Johansen estimator and its parametric counterpart are small. Further-
more, the bootstrapped variances of the incidence proportion, of the probability trans-
form of the incidence density accounting for CEs and of the Aalen-Johansen estimator are
comparable to the model-based ones.
4.3 Estimating the relative risk
In the data example, estimators that overestimate the AE probability underestimate the
relative risk. This is further investigated in the simulations.
Table 5 displays the truemean relative risk andmean relative risk where the probabili-
ties were calculated by the Aalen-Johansen estimator. The relative risk calculated with the
17
Aalen-Johansen estimator is comparable to the true relative risk. The different scenarios
consider situations of a larger probability in group A (scenario S2, S3 and S10 at τP60) and
of a smaller probability in group A (scenario S5 and S10 except τP60).
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Figure 5: Boxplots of the difference between the relative risk of the estimators of interest
and the Aalen-Johansen estimator (absolute bias with respect to the Aalen-Johansen esti-
mator). The following follow-up times are considered τ
(A)
max,τ
(B)
max the maximum follow-
up times in group A and group B respectively, τmax the minimum of the two maximal
event times, τP90 and τP60 chosen according to the quantiles of the time and account for
different lengths of follow-up between group A and group B. (N = 1000)
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Table 6: Simulation results: Mean ratio of the relative risk of the estimator of interest
and the relative risk calculated by the Aalen-Johansen estimator (AJE) - 1 (mean relative
bias w.r.t. Aalen-Johansen). The following follow-up times are considered τ
(A)
max,τ
(B)
max the
maximum follow-up times in group A and group B respectively, τmax the minimum of
the two maximal event times, τP90 and τP60 chosen according to the quantiles of the time
and account for different lengths of follow-up between group A and group B. For a better
display probability transform is abbreviated by PT. (N = 1000)
Scenario
Follow-up time Estimator S2 S3 S5 S10
τ
(A)
max, τ
(B)
max Incidence proportion 0.0000 -0.0290 -0.1419 0.0057
τ
(A)
max, τ
(B)
max PT incidence density -0.1369 -0.1257 0.7477 0.1286
τ
(A)
max, τ
(B)
max 1-Kaplan-Meier -0.1319 -0.1186 3.9105 0.1321
τ
(A)
max, τ
(B)
max PT incidence density CE -0.0001 0.0004 -0.1258 0.0002
τmax Incidence proportion 0.0000 -0.0249 -0.1294 0.0047
τmax PT incidence density -0.1571 -0.1317 0.4363 0.1370
τmax 1-Kaplan-Meier -0.1558 -0.1269 2.1821 0.1449
τmax PT incidence density CE 0.0007 0.0010 -0.1561 -0.0035
τP90 Incidence proportion 0.0000 -0.0081 -0.0471 0.0014
τP90 PT incidence density -0.1043 -0.0869 -0.0220 0.1192
τP90 1-Kaplan-Meier -0.1094 -0.0887 0.1678 0.1229
τP90 PT incidence density CE 0.0015 0.0011 -0.0992 -0.0002
τP60 Incidence proportion 0.0000 -0.0017 -0.0130 0.0002
τP60 PT incidence density -0.0529 -0.0428 -0.0267 0.0704
τP60 1-Kaplan-Meier -0.0553 -0.0441 0.0149 0.0725
τP60 PT incidence density CE 0.0015 0.0009 -0.0315 0.0042
The boxplots in Figure 5 display the absolute mean bias with respect to the Aalen-
Johansen estimator resulting from the other estimators. Using the incidence proportion
or the probability transform of the incidence density accounting for CEs instead of the
Aalen-Johansen estimator when comparing two treatment groups in terms of the rela-
tive risk induced no bias in the scenarios with constant hazards without censoring and
time-dependent hazards. In the scenario with constant hazards and censoring (scenario
S3) there are simulated datasets where the relative risk using the incidence proportion
and probability transform of the incidence density accounting for CEs is either greater or
smaller than the effect found by the Aalen-Johansen estimator.
Using either the probability transform of the incidence density or the 1-Kaplan-Meier
estimator the relative risk is smaller than the relative risk calculated with the Aalen-
Johansen estimator in scenario S2 and S3 where there is a beneficial effect of B but higher
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in scenario S5 at τ
(A)
max, τ
(B)
max and τmax and in scenario S10 at τ
(A)
max, τ
(B)
max, τmax and
τP90 where a positive effect of A is simulated. But if there are severe differences between
the two treatment groups A and B (scenario S5 at τP90 and τP60) using the probability
transform of the incidence density may also result in a smaller relative risk than using the
Aalen-Johansen estimator even though there is a beneficial effect of A observed.
The same conclusions can be drawn by considering the mean relative bias w.r.t. the
Aalen-Johansen estimator of the relative risk (Table 6). The relative risks calculated by the
incidence proportion or the probability transform of the incidence density accounting for
CEs show the most difference to the relative risk calculated by the Aalen-Johansen esti-
mator in scenario S5. At the maximum follow-up time, the relative risk calculated by the
incidence proportion is on average 14.15% smaller than the relative risk calculated by the
Aalen-Johansen estimator. The average relative ratio of the relative risk calculated with
the probability transform of the incidence density and the relative risk calculated with
the Aalen-Johansen estimator is between 4% and 16% in the scenarios S2 and S3. In sce-
nario S5 at the maximum follow-up time the average mean ratio is the most pronounced.
There the relative risk calculated by the Kaplan-Meier estimator is five times the size of
the relative risk calculated by the gold-standard method.
5 Conclusions and Discussion
In this paper, we compared several estimators quantifying the AE probability. The gold-
standard estimator of this probability in a time-to-event analysis with CEs is the Aalen-
Johansen estimator. But simulations and the real data example illustrated that using the
probability transform of the incidence density accounting for CEs or the incidence pro-
portion may also provide unbiased estimates as long as the hazards are constant or there
is no censoring at the considered follow-up time. The latter is usually not the case when
adverse events are monitored during an ongoing trial by e.g. a data monitoring commit-
tee or a data safety monitoring board. These situations would be typically characterized
by high amounts of censored observations.
Often in AE analyses there are many CEs as progression, treatment discontinuation
or death and only few observations may be censored. Therefore, the use of the incidence
proportion may often be justified if censoring is low and the CEs have been specified ap-
propriately. This emphasizes the need to consider thoroughly how the competing events
are defined in the specific trial as this directly impacts the amount of censoring. We do,
however, recommend as a general rule to use one common τ when comparing incidence
proportions, especially instead of the group specific maximal follow-up times if they dif-
fer. Moreover, the probability transform of the incidence density and the 1-Kaplan-Meier
estimator always overestimate in the presence of CEs. A similar result was found when
considering the relative risk. Using the 1-Kaplan-Meier estimator or the probability trans-
form of the incidence density may result in the opposite conclusion about a therapy’s
safety as compared to using the Aalen-Johansen estimator. To summarize, in the litera-
ture5,21,13 mainly the constant hazards assumption is criticized, but one of our main re-
sults is that ignoring CEs and treating them falsely by censoring at the event time may
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be worse than misspecifying the model by falsely assuming constant hazards. This also
calls for a larger emphasis on competing risk in the epidemiology literature on incidence
densities.
This paper emphazises the need to carefully consider the different follow-up times
in safety analyses. One reason is that due to a small number of patients still at risk at
the end of follow-up the variances of the estimators may be increased.12 Another aspect
with different follow-up times between groups is to calculate the relative risk using one
common time point in both groups as otherwise the interpretation may be difficult.11
Here, we only considered the relative risk. But similar conclusions can be drawn for the
risk difference (results not shown).
We further compared the model-based and the bootstrapped variance estimates of
the estimators. Thereby, for the incidence proportion, the Kaplan-Meier estimator, the
probability transform of the incidence density accounting for CEs and the Aalen-Johansen
estimator no relevant differences between the two variance estimators were found. For
the probability transform of the incidence density we found a smaller estimated variance
for the model-based approach than for the bootstrapped one. The model-based variance
assumes constant hazards whereas the non-parametric bootstrapped variance estimator
does not rely on this assumption.10
To summarize and to get back to the three questions this paper adds to the discussion
about the analyses of AEs from the introduction: The answer to question (i) is that the
choice of the estimator is also crucial for group comparisons in terms of the relative risk.
The bias in calculating the AE probabilities and variances of the AE probabilities do also
directly influence the relative risk and the confidence intervals. Regarding question (ii),
since the probability transform of the incidence density accounting for CEs is less biased
with respect to the Aalen-Johansen estimator than of 1-Kaplan-Meier estimator, ignoring
CEs is worse than falsely assuming constant hazards. When then considering question
(iii), for earlier time points of analysis for most AE probability and relative risk estima-
tors the bias with respect to the Aalen-Johansen estimator is smaller. Especially, for the
incidence proportion the bias is almost negligible.
These analyses are motivated by the Survival analysis for AdVerse events with VarY-
ing follow-up times project (SAVVY).22 This is a joint project of academic institutions and
pharmaceutical companies with the aim to improve standards for the reporting of inci-
dences of adverse events. This project includes an empirical study calculating the above
mentioned estimators in several randomized controlled trials and summarizing the re-
sults in a meta-analysis to assess the sources of bias in more real safety analyses.
AEs may also be recurrent21, but the issue of CEs will remain as relevant as in time-
to-first-event analyses. Recent papers by Charles-Nelson et al.23 and by Andersen et al.24
emphazise the importance of considering competing (terminal) events also in analyses of
recurrent events. See21,25,26 for suggestions on the analysis of recurrent AEs.
Moreover, here we focused on the comparison of probabilities and of the ratio of prob-
abilities (relative risk) instead of the comparison of hazards. Interpretation of hazards and
hazard ratios is often challenging in particular in the presence of CEs.27 The best way to
communicate results is by visualizing the estimated probabilities for the two groups. All
22
estimators introduced in Section 2 can easily be visualized in plots (see Figure 2), although
theses plots do not provide direct information about the possible dynamic pattern of the
treatment effect.28 Here, to better understand the differences between the estimated AE
probabilities in the data example, we also considered a plot of the cumulative hazards es-
timated by the Nelson-Aalen estimator in Figure 3. Therefore, as most analyses consider
both the probabilities and the hazards one other point of future research and embedded
in the SAVVY project is to compare different estimators of the hazard ratio, e.g., the haz-
ard ratio obtained by the Cox proportional hazards model, the ratio of the Nelson-Aalen
estimators and the ratio of the incidence density of both groups.
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A Proof: The estimand of the 1-Kaplan-Meier estimator is greater
than the cumulative incidence function
For the cumulative incidence function (left-hand side below) that can be estimated by the
Aalen-Johansen estimator and the estimand of the 1-Kaplan-Meier estimator (right-hand
23
side) the following inequality holds:
P(T 6 t, ǫ = 1| group A) =
t∫
0
P(T > u− | group A)λA(u)du =
t∫
0
exp
− u∫
0
λA(s) + λ¯A(s)ds
 λA(u)du
⋆
6
t∫
0
exp
− u∫
0
λA(s)ds
 λA(u)du = 1− exp
− t∫
0
λA(u)du

where relation ⋆ holds since exp
(
−
u∫
0
λ¯A(s)ds
)
6 1 with equality if λ¯A(s) = 0∀s, i.e.,
no CEs are present in the data. Note that relation ⋆ does not postulate the existence of la-
tent event-specific times. As a consequence, exp
(
−
t∫
0
λA(s)ds
)
has no proper probability
interpretation in settings with CEs.
B Model-based variances of the probability transform of the in-
cidence density accounting for CEs
It is known that
√
n
(
(ÎDA, ÎDA)
T − (θ1, θ2)
T
)
d→ Z ∼ N
((
0
0
)
,
(
var(θ1) 0
0 var(θ2)
))
.
and that the variance of the CE incidence density can be estimated analogously to the
incidence density of the AE:
var(ÎDA) =
∑
u∈[0,τ]
d¯A(u)(
nA∑
i=1
min(ti, τ)
)2 .
The following mapping is defined to transform the two incidence densities to the estima-
tor accounting for CEs on the probability scale:
Φ(x,y) =
(1− exp(−τ(x+ y))) · x
(x+ y)
Then the multivariate delta-method can be applied and the holds:
√
n(Φ(ÎDA, ÎDA) −Φ(θ1, θ2))
d→ Φ ′(θ1, θ2)Z ∼ N(0, s2A)
24
where s2A is the variance of the probability transform of the incidence density and can be
estimated by
sˆ2A =
exp(−τ · ÎD•A(τ)) · ÎDA(τ) ·
(
exp(τ · ÎD•A(τ)) − 1
)
+ τ · ÎDA(τ) · ÎD•A(τ)
ÎD•A(τ)2
2 · v̂ar(ÎDA(τ))
+
ÎDA(τ) · exp(−τ · ÎD•A(τ)) · τ · ÎD•A(τ) − exp
(
τ · ÎD•A(τ)
)
+ 1
ÎD•A(τ)2
2 · v̂ar(ÎDA(τ)).
with ÎD•A(τ) = ÎDA(τ) + ÎDA(τ)
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